A randomized, observer-blind trial of amoxycillin/clavulanate versus cefaclor in the treatment of children with acute otitis media. Augmentin 415 Study Group.

In this randomized, multicenter, observer-blind study, the efficacy, safety and tolerability of amoxycillin/clavulanate and cefaclor were compared in children with a clinical diagnosis of acute otitis media. Patients aged between 1 and 12 years received either amoxycillin/clavulanate (250 mg/62 mg t.i.d., or 125 mg/31 mg t.i.d. if aged under 6 years) or cefaclor (250 mg t.i.d., or 125 mg t.i.d. if aged under 6 years) for 7 days. The amoxycillin/clavulanate regimen was based on a dose of 20/5 mg/kg/day (representing 20 mg amoxycillin plus 5 mg clavulanic acid) in three divided doses. Patients were followed-up at the end of therapy and on days 10-12 and 38-40. At the end of the study (days 38-40), clinical success rates were 91.4% for amoxycillin/clavulanate and 78.6% for cefaclor. The difference was statistically significant (p = 0.008). After the 7 days of treatment, 3 patients (2.9%) in the amoxycillin/clavulanate group had clinical failure, compared with 18 patients (16.1%) in the cefaclor group (p < 0.001). Both treatments were well tolerated and there were no statistically significant differences between the groups in adverse event profiles. The incidence of diarrhea was low (7.0% amoxycillin/clavulanate, 8.4% cefaclor) and was generally of mild or moderate intensity. The study demonstrated that amoxycillin/clavulanate was significantly more effective clinically than cefaclor in the treatment of acute otitis media in children.

Estudo clinico multicentrico com bactroban creme (mupirocina, 2 por cento) no tratamento de infeccoes cutaneas na infancia e adolescencia / Open multicenter trial with mupirocin 2 percent in the treatment of skin infection of children and adolescents

Em estudo aberto, nao comparativo, envolvendo quatro centros, 116 criancas e adolescentes portadores de infecoes cutaneas foram avaliados. Destes 68 eram do sexo masculino e 48 do sexo feminino, com idades entre 21 a 15 anos. O tratamento consistiu da administracao de bactroban creme (mupirocina,2 por cento) tres vezes ao dia, por um periodo nao menor que 5 dias .Impetigo foi o diagnostico mais comum em infecoes primarias enquanto escoriacao infectada foi mais prevalente em infeccoes secundarias de pele. O germe mais frequente foi Staphylococcus aureus. A duracao media do tratamento foi de 7,35 dias,ocorrendo cura do processo infeccioso em 106 pacientes (91,38 por cento) melhora em 9 pacientes (7,76 por cento) e insucesso em apenas 1 paciente (0,86 por cento). Os resultados confirmam ser o bactroban creme (mupirocina,2 por cento)um excelente antibiotico topico para o tratamento de infeccoes cutaneas em crianca e adolescentes.